Abstract
Insulinomas are rare neuroendocrine tumors which occur predominantly in the pancreas. Although majority of the insulinomas are benign, over-secretion of insulin by the tumor leads to debilitating hypoglycemic symptoms. The diagnosis is based on clinical and biochemical findings. After the diagnosis is made, the principal challenge lies in locating the tumor because most tumors are solitary and small in size. Locating the tumor is of paramount importance as complete surgical excision is the only curative treatment, and incomplete resection leads to persistence of symptoms. Different preoperative and intraoperative imaging techniques have been used with varying success rates for the insulinoma imaging. Besides localizing the tumor, imaging also helps to guide biopsy, detect metastatic lesions, and perform image-guided therapeutic procedures. This review will discuss the role of different Cross sectional and nuclear medicine imaging modalities in insulinomas.
Similar content being viewed by others
References
Rindi G, Kloppel G (2004) Endocrine tumors of the gut and pancreas tumor biology and classification. Neuroendocrinology 80(Suppl 1):12–15. doi:10.1159/000080733
Service FJ, McMahon MM, O’Brien PC, Ballard DJ (1991) Functioning insulinoma–incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc 66(7):711–719
Mehrabi A, Fischer L, Hafezi M, et al. (2014) A systematic review of localization, surgical treatment options, and outcome of insulinoma. Pancreas 43(5):675–686. doi:10.1097/MPA.0000000000000110
Kloppel G, Heitz PU (1988) Pancreatic endocrine tumors. Pathol Res Pract 183(2):155–168. doi:10.1016/S0344-0338(88)80043-8
de Herder WW, Niederle B, Scoazec JY, et al. (2006) Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology 84(3):183–188. doi:10.1159/000098010
Callender GG, Rich TA, Perrier ND (2008) Multiple endocrine neoplasia syndromes. Surg Clin North Am 88(4):863–895 (viii.). doi:10.1016/j.suc.2008.05.001
Service FJ (1995) Hypoglycemic disorders. N Engl J Med 332(17):1144–1152. doi:10.1056/NEJM199504273321707
O’Riordain DS, O’Brien T, van Heerden JA, Service JA, Grant CS (1994) Surgical management of insulinoma associated with multiple endocrine neoplasia type I. World J Surg 18(4):488–493
Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25(3):458–511. doi:10.1210/er.2003-0014
Oberg K, Eriksson B (2005) Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol 19(5):753–781. doi:10.1016/j.bpg.2005.06.002
Whipple AO, Frantz VK (1935) Adenoma of islet cells with hyperinsulinism: a review. Ann Surg 101(6):1299–1335
Hirshberg B, Livi A, Bartlett DL, et al. (2000) Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab 85(9):3222–3226. doi:10.1210/jcem.85.9.6807
Rindi G, Kloppel G, Alhman H, et al. (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395–401. doi:10.1007/s00428-006-0250-1
Stefanini P, Carboni M, Patrassi N, Basoli A (1974) Beta-islet cell tumors of the pancreas: results of a study on 1,067 cases. Surgery 75(4):597–609
Gorman B, Charboneau JW, James EM, et al. (1986) Benign pancreatic insulinoma: preoperative and intraoperative sonographic localization. AJR Am J Roentgenol 147(5):929–934. doi:10.2214/ajr.147.5.929
Gunther RW, Klose KJ, Ruckert K, et al. (1985) Localization of small islet-cell tumors. preoperative and intraoperative ultrasound, computed tomography, arteriography, digital subtraction angiography, and pancreatic venous sampling. Gastrointest Radiol 10(2):145–152
Tucker ON, Crotty PL, Conlon KC (2006) The management of insulinoma. Br J Surg 93(3):264–275. doi:10.1002/bjs.5280
Ravi K, Britton BJ (2007) Surgical approach to insulinomas: are pre-operative localisation tests necessary? Ann R Coll Surg Engl 89(3):212–217. doi:10.1308/003588407X179008
Angeli E, Vanzulli A, Castrucci M, et al. (1997) Value of abdominal sonography and MR imaging at 0.5 T in preoperative detection of pancreatic insulinoma: a comparison with dynamic CT and angiography. Abdom Imaging 22(3):295–303
D’Onofrio M, Barbi E, Dietrich CF, et al. (2012) Pancreatic multicenter ultrasound study (PAMUS). Eur J Radiol 81(4):630–638. doi:10.1016/j.ejrad.2011.01.053
An L, Li W, Yao KC, et al. (2011) Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma. Eur J Radiol 80(3):675–680. doi:10.1016/j.ejrad.2010.09.014
D’Onofrio M, Mansueto G, Vasori S, Falconi M, Procacci C (2003) Contrast-enhanced ultrasonographic detection of small pancreatic insulinoma. J Ultrasound Med 22(4):413–417
Horino T, Takao T, Hashimoto K (2006) A case with insulinoma diagnosed and localized preoperatively using contrast-enhanced ultrasonography (CEUS) and arterial stimulation and venous sampling (ASVS). Endocr J 53(1):141–146
Ardengh JC, Rosenbaum P, Ganc AJ, et al. (2000) Role of EUS in the preoperative localization of insulinomas compared with spiral CT. Gastrointest Endosc 51(5):552–555
Zimmer T, Stolzel U, Bader M, et al. (1996) Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut 39(4):562–568
Pitre J, Soubrane O, Palazzo L, Chapuis Y (1996) Endoscopic ultrasonography for the preoperative localization of insulinomas. Pancreas 13(1):55–60
Glover JR, Shorvon PJ, Lees WR (1992) Endoscopic ultrasound for localisation of islet cell tumours. Gut 33(1):108–110
Schumacher B, Lubke HJ, Frieling T, Strohmeyer G, Starke AA (1996) Prospective study on the detection of insulinomas by endoscopic ultrasonography. Endoscopy 28(3):273–276. doi:10.1055/s-2007-1005452
Sotoudehmanesh R, Hedayat A, Shirazian N, et al. (2007) Endoscopic ultrasonography (EUS) in the localization of insulinoma. Endocrine 31(3):238–241
Kann PH, Ivan D, Pfutzner A, et al. (2007) Preoperative diagnosis of insulinoma: low body mass index, young age, and female gender are associated with negative imaging by endoscopic ultrasound. Eur J Endocrinol 157(2):209–213. doi:10.1530/EJE-07-0117
Jurgensen C, Schuppan D, Neser F, et al. (2006) EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 63(7):1059–1062. doi:10.1016/j.gie.2005.10.034
Kasono K, Hyodo T, Suminaga Y, et al. (2002) Contrast-enhanced endoscopic ultrasonography improves the preoperative localization of insulinomas. Endocr J 49(4):517–522
Qin SY, Lu XP, Jiang HX (2014) EUS-guided ethanol ablation of insulinomas: case series and literature review. Medicine (Baltimore) 93(14):e85. doi:10.1097/MD.0000000000000085
Yang D, Inabnet WB 3rd, Sarpel U, DiMaio CJ (2015) EUS-guided ethanol ablation of symptomatic pancreatic insulinomas. Gastrointest Endosc 82(6):1127. doi:10.1016/j.gie.2015.06.030
Levy MJ, Thompson GB, Topazian MD, et al. (2012) US-guided ethanol ablation of insulinomas: a new treatment option. Gastrointest Endosc 75(1):200–206. doi:10.1016/j.gie.2011.09.019
Lakhtakia S, Ramchandani M, Galasso D, et al. (2016) EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 83(1):234–239. doi:10.1016/j.gie.2015.08.085
Wong M, Isa SH, Zahiah M, Azmi KN (2007) Intraoperative ultrasound with palpation is still superior to intra-arterial calcium stimulation test in localising insulinoma. World J Surg 31(3):586–592. doi:10.1007/s00268-006-0106-5
Norton JA, Sigel B, Baker AR, et al. (1985) Localization of an occult insulinoma by intraoperative ultrasonography. Surgery 97(3):381–384
Hiramoto JS, Feldstein VA, LaBerge JM, Norton JA (2001) Intraoperative ultrasound and preoperative localization detects all occult insulinomas. Arch Surg 136(9):1020–1025 (discussion 1025-6)
Gouya H, Vignaux O, Augui J, et al. (2003) CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 181(4):987–992. doi:10.2214/ajr.181.4.1810987
London NJ, Bolia A, Millac P, James RF, Bell PR (1988) Localization of an occult impalpable insulinoma by intraoperative ultrasonography. J R Soc Med 81(11):663–664
Norton JA (1999) Intraoperative methods to stage and localize pancreatic and duodenal tumors. Ann Oncol 10(Suppl 4):182–184
Zografos GN, Stathopoulou A, Mitropapas G, et al. (2005) Preoperative imaging and localization of small sized insulinoma with EUS-guided fine needle tattoing: a case report. Hormones (Athens) 4(2):111–116
Noone TC, Hosey J, Firat Z, Semelka RC (2005) Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab 19(2):195–211. doi:10.1016/j.beem.2004.11.013
Liu Y, Song Q, Jin HT, Lin XZ, Chen KM (2009) The value of multidetector-row CT in the preoperative detection of pancreatic insulinomas. Radiol Med 114(8):1232–1238. doi:10.1007/s11547-009-0466-7
King AD, Ko GT, Yeung VT, et al. (1998) Dual phase spiral CT in the detection of small insulinomas of the pancreas. Br J Radiol 71(841):20–23. doi:10.1259/bjr.71.841.9534694
Bao ZK, Huang XY, Zhao JG, et al. (2010) A case of occult insulinoma localized by pancreatic dynamic enhanced spiral CT. World J Gastroenterol 16(11):1418–1421
Lin XZ, Wu ZY, Tao R, et al. (2012) Dual energy spectral CT imaging of insulinoma-value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol 81(10):2487–2494. doi:10.1016/j.ejrad.2011.10.028
McAuley G, Delaney H, Colville J, et al. (2005) Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol 60(10):1039–1050. doi:10.1016/j.crad.2005.06.005
Thoeni RF, Mueller-Lisse UG, Chan R, Do NK, Shyn PB (2000) Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 214(2):483–490. doi:10.1148/radiology.214.2.r00fe32483
Semelka RC, Custodio CM, Cem Balci N, Woosley JT (2000) Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI. J Magn Reson Imaging 11(2):141–148
Kraus BB, Ros PR (1994) Insulinoma: diagnosis with fat-suppressed MR imaging. AJR Am J Roentgenol 162(1):69–70. doi:10.2214/ajr.162.1.8273692
Anaye A, Mathieu A, Closset J, et al. (2009) Successful preoperative localization of a small pancreatic insulinoma by diffusion-weighted MRI. JOP 10(5):528–531
Druce MR, Muthuppalaniappan VM, O’Leary B, et al. (2010) Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol 162(5):971–978. doi:10.1530/EJE-10-0056
Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30(5):781–793. doi:10.1007/s00259-003-1184-3
Korner M, Stockli M, Waser B, Reubi JC (2007) GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 48(5):736–743. doi:10.2967/jnumed.106.038679
Estall JL, Drucker DJ (2006) Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 12(14):1731–1750
Antwi K, Fani M, Nicolas G, et al. (2015) Localization of hidden insulinomas with (6)(8)Ga-DOTA-Exendin-4 PET/CT: a pilot study. J Nucl Med 56(7):1075–1078. doi:10.2967/jnumed.115.157768
Christ E, Wild D, Forrer F, et al. (2009) Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J Clin Endocrinol Metab 94(11):4398–4405. doi:10.1210/jc.2009-1082
Christ E, Wild D, Ederer S, et al. (2013) Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study. Lancet Diabetes Endocrinol 1(2):115–122. doi:10.1016/S2213-8587(13)70049-4
Luo Y, Yu M, Pan Q, et al. (2015) 68 Ga-NOTA-exendin-4 PET/CT in detection of occult insulinoma and evaluation of physiological uptake. Eur J Nucl Med Mol Imaging 42(3):531–532. doi:10.1007/s00259-014-2946-9
Luo Y, Li N, Kiesewetter DO, Chen X, Li F (2016) 68 Ga-NOTA-Exendin-4 PET/CT in localization of an occult insulinoma and appearance of coexisting esophageal carcinoma. Clin Nucl Med 41(4):341–343. doi:10.1097/RLU.0000000000001087
Sowa-Staszczak A, Pach D, Mikolajczak R, et al. (2013) Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma. Eur J Nucl Med Mol Imaging 40(4):524–531. doi:10.1007/s00259-012-2299-1
Wild D, Christ E, Caplin ME, et al. (2011) Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J Nucl Med 52(7):1073–1078. doi:10.2967/jnumed.110.085142
Eriksson O, Velikyan I, Selvaraju RK, et al. (2014) Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report. J Clin Endocrinol Metab 99(5):1519–1524. doi:10.1210/jc.2013-3541
Reubi JC (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 24(4):389–427. doi:10.1210/er.2002-0007
Vezzosi D, Bennet A, Rochaix P, et al. (2005) Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol 152(5):757–767. doi:10.1530/eje.1.01901
Kulaksiz H, Eissele R, Rossler D, et al. (2002) Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50(1):52–60
Portela-Gomes GM, Stridsberg M, Grimelius L, Rorstad O, Janson ET (2007) Differential expression of the five somatostatin receptor subtypes in human benign and malignant insulinomas: predominance of receptor subtype 4. Endocr Pathol 18(2):79–85
Balon HR, Brown TL, Goldsmith SJ, et al. (2011) The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol 39(4):317–324. doi:10.2967/jnmt.111.098277
Schillaci O, Massa R, Scopinaro F (2000) 111In-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med 41(3):459–462
Reubi JC, Schar JC, Waser B, et al. (2000) Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27(3):273–282
Prasad V, Sainz-Esteban A, Arsenic R, et al. (2016) Role of Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. Eur J Nucl Med Mol Imaging . doi:10.1007/s00259-016-3331-7
Sharma P, Dhull VS, Arora S, et al. (2014) Diagnostic accuracy of (68)Ga-DOTANOC PET/CT imaging in pheochromocytoma. Eur J Nucl Med Mol Imaging 41(3):494–504. doi:10.1007/s00259-013-2598-1
Treglia G, Inzani F, Campanini N, et al. (2013) A case of insulinoma detected by (68)Ga-DOTANOC PET/CT and missed by (18)F-dihydroxyphenylalanine PET/CT. Clin Nucl Med 38(6):e267–e270. doi:10.1097/RLU.0b013e31825b222f
Sadowski SM, Neychev V, Cottle-Delisle C, et al. (2014) Detection of insulinoma using (68)Gallium-DOTATATE PET/CT: a case report. Gland Surg 3(4):E1–E5. doi:10.3978/j.issn.2227-684X.2014.10.02
Makis W, McCann K, McEwan AJ (2016) Metastatic insulinoma pancreatic neuroendocrine tumor treated with 177Lu-DOTATATE induction and maintenance peptide receptor radionuclide therapy: a suggested protocol. Clin Nucl Med 41(1):53–54. doi:10.1097/RLU.0000000000001023
Costa R, Costa R, Bacchi CE, Almeida Filho P (2013) Metastatic insulinoma managed with radiolabeled somatostatin analog. Case Rep Endocrinol 2013:252159. doi:10.1155/2013/252159
Pincus DW, DiCicco-Bloom EM, Black IB (1990) Vasoactive intestinal peptide regulates mitosis, differentiation and survival of cultured sympathetic neuroblasts. Nature 343(6258):564–567. doi:10.1038/343564a0
Virgolini I, Yang Q, Li S, et al. (1994) Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res 54(3):690–700
Virgolini I, Kurtaran A, Raderer M, et al. (1995) Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med 36(10):1732–1739
Virgolini I, Raderer M, Kurtaran A, et al. (1994) Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med 331(17):1116–1121. doi:10.1056/NEJM199410273311703
Raderer M, Kurtaran A, Leimer M, et al. (2000) Value of peptide receptor scintigraphy using (123)I-vasoactive intestinal peptide and (111)In-DTPA-D-Phe1-octreotide in 194 carcinoid patients: Vienna University Experience, 1993–1998. J Clin Oncol 18(6):1331–1336
Virgolini I, Raderer M, Kurtaran A, et al. (1996) 123I-vasoactive intestinal peptide (VIP) receptor scanning: update of imaging results in patients with adenocarcinomas and endocrine tumors of the gastrointestinal tract. Nucl Med Biol 23(6):685–692
Adams S, Baum R, Rink T, et al. (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25(1):79–83
Kayani I, Bomanji JB, Groves A, et al. (2008) Functional imaging of neuroendocrine tumors with combined PET/CT using 68 Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDG. Cancer 112(11):2447–2455. doi:10.1002/cncr.23469
Kamaleshwaran KK, Bhattacharya A, Chakraborty D, Manohar K, Mittal BR (2010) Diffusely increased muscular uptake of [18F]fluorodeoxyglucose: a clue for the diagnosis of insulinoma? Eur J Nucl Med Mol Imaging 37(9):1800. doi:10.1007/s00259-010-1515-0
Basu S (2015) Indirect evidences of functionality of insulinoma on FDG-PET: the ‘whole body-metabolism’ advantage and its clinical implications. Indian J Cancer 52(1):68–69. doi:10.4103/0019-509X.175558
Kauhanen S, Seppanen M, Minn H, et al. (2007) Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab 92(4):1237–1244. doi:10.1210/jc.2006-1479
Tessonnier L, Sebag F, Ghander C, et al. (2010) Limited value of 18F-F-DOPA PET to localize pancreatic insulin-secreting tumors in adults with hyperinsulinemic hypoglycemia. J Clin Endocrinol Metab 95(1):303–307. doi:10.1210/jc.2009-1357
Peranteau WH, Palladino AA, Bhatti TR, et al. (2013) The surgical management of insulinomas in children. J Pediatr Surg 48(12):2517–2524. doi:10.1016/j.jpedsurg.2013.04.022
Imperiale A, Sebag F, Vix M, et al. (2015) 18F-FDOPA PET/CT imaging of insulinoma revisited. Eur J Nucl Med Mol Imaging 42(3):409–418. doi:10.1007/s00259-014-2943-z
Padidela R, Fiest M, Arya V, et al. (2014) Insulinoma in childhood: clinical, radiological, molecular and histological aspects of nine patients. Eur J Endocrinol 170(5):741–747. doi:10.1530/EJE-13-1008
Di Gialleonardo V, Signore A, Scheerstra EA, et al. (2012) 11C-hydroxytryptophan uptake and metabolism in endocrine and exocrine pancreas. J Nucl Med 53(11):1755–1763. doi:10.2967/jnumed.112.104117
Orlefors H, Sundin A, Garske U, et al. (2005) Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab 90(6):3392–3400. doi:10.1210/jc.2004-1938
Orlefors H, Sundin A, Eriksson B, et al. (2012) PET-guided surgery: high correlation between positron emission tomography with 11C-5-Hydroxytryptophane (5-HTP) and surgical findings in abdominal neuroendocrine tumours. Cancers (Basel) 4(1):100–112. doi:10.3390/cancers4010100
Gotthardt M, Behe MP, Beuter D, et al. (2006) Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33(11):1273–1279. doi:10.1007/s00259-006-0157-8
Schulz S, Rocken C, Mawrin C, Schulz S (2005) Immunohistochemical localization of CCK1 cholecystokinin receptors in normal and neoplastic human tissues. J Clin Endocrinol Metab 90(11):6149–6155. doi:10.1210/jc.2005-0172
Gotthardt M, Behe MP, Grass J, et al. (2006) Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 13(4):1203–1211. doi:10.1677/erc.1.01245
Crippa S, Zerbi A, Boninsegna L, et al. (2012) Surgical management of insulinomas: short- and long-term outcomes after enucleations and pancreatic resections. Arch Surg 147(3):261–266. doi:10.1001/archsurg.2011.1843
Mabrut JY, Fernandez-Cruz L, Azagra JS, et al. (2005) Laparoscopic pancreatic resection: results of a multicenter European study of 127 patients. Surgery 137(6):597–605
Ayav A, Bresler L, Brunaud L, et al. (2005) Laparoscopic approach for solitary insulinoma: a multicentre study. Langenbecks Arch Surg 390(2):134–140. doi:10.1007/s00423-004-0526-3
Park BJ, Alexander HR, Libutti SK, et al. (1998) Operative management of islet-cell tumors arising in the head of the pancreas. Surgery 124(6):1056–1061 (discussion 1061-1052)
Ramage JK, Davies AH, Ardill J, et al. (2005) Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut . doi:10.1136/gut.2004.053314
Hirshberg B, Libutti SK, Alexander HR, et al. (2002) Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg 194(6):761–764
Sarmiento JM, Heywood G, Rubin J, et al. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37. doi:10.1016/S1072-7515(03)00230-8
Grama D, Eriksson B, Martensson H, et al. (1992) Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes. World J Surg 16(4):632–639
Brentjens R, Saltz L (2001) Islet cell tumors of the pancreas: the medical oncologist’s perspective. Surg Clin North Am 81(3):527–542
Eriksson B, Annibale B, Bajetta E, et al. (2009) ENETS consensus guidelines for the standards of care in neuroendocrine tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 90(2):214–219. doi:10.1159/000225950
Chen J, Wang C, Han J, et al. (2013) Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma. Expert Rev Anticancer Ther 13(6):737–743. doi:10.1586/era.13.45
Starke A, Saddig C, Mansfeld L, et al. (2005) Malignant metastatic insulinoma-postoperative treatment and follow-up. World J Surg 29(6):789–793. doi:10.1007/s00268-005-7743-y
Kennedy AS, Dezarn WA, McNeillie P, et al. (2008) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31(3):271–279. doi:10.1097/COC.0b013e31815e4557
Kennedy A, Bester L, Salem R, et al. (2015) Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford) 17(1):29–37. doi:10.1111/hpb.12326
Bernard V, Lombard-Bohas C, Taquet MC, et al. (2013) Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia. Eur J Endocrinol 168(5):665–674. doi:10.1530/EJE-12-1101
Kulke MH, Bergsland EK, Yao JC (2009) Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 360(2):195–197. doi:10.1056/NEJMc0806740
Bourcier ME, Sherrod A, DiGuardo M, Vinik AI (2009) Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 94(9):3157–3162. doi:10.1210/jc.2009-0788
Gill GV, Rauf O, MacFarlane IA (1997) Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J 73(864):640–641
Kwekkeboom DJ, de Herder WW, Kam BL, et al. (2008) Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 26(13):2124–2130. doi:10.1200/JCO.2007.15.2553
Fischbach J, Gut P, Matysiak-Grzes M, et al. (2012) Combined octreotide and peptide receptor radionuclide therapy ((90)Y-DOTA-TATE) in case of malignant insulinoma. Neuro Endocrinol Lett 33(3):273–278
Kwekkeboom DJ, Teunissen JJ, Bakker WH, et al. (2005) Radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23(12):2754–2762. doi:10.1200/JCO.2005.08.066
van Schaik E, van Vliet EI, Feelders RA, et al. (2011) Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab 96(11):3381–3389. doi:10.1210/jc.2011-1563
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Rayamajhi, S.J., Lee, J., Mittal, B.R. et al. Cross sectional and nuclear medicine imaging of pancreatic insulinomas. Abdom Radiol 42, 531–543 (2017). https://doi.org/10.1007/s00261-016-0904-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00261-016-0904-7